Titan Medical Inc. announced senior leadership changes and the receipt of a notification from the Nasdaq Stock Market LLC Listing Qualifications Department stating that following the resignation of Heather Knight from the Company's board of directors and audit committee, the Company no longer complies with Nasdaq's audit committee requirement set forth in Nasdaq Rule 5605. Following the announcement of February 8, 2023, the Company has decided to layoff certain members of the Company's senior leadership team. Each of these individuals remain available to assist the Company as independent consultants.

The following changes are effective immediately: Tammy Carrea is no longer VP, Quality and Regulatory Affairs of the Company. Ms. Carrea will continue to assist the Company, as needed, as an independent consultant with quality and regulatory matters, and to assist with the strategic review process; Kristen Galfetti is no longer VP, Investor Relations and Corporate Communications of the Company. Ms. Galfetti will continue to assist the Company, as needed, as an independent consultant with investor relations and corporate communications, and to assist with the strategic review process; Eric Heinz is no longer VP, Market and Corporate Development of the Company.

Mr. Heinz will continue to assist the Company, as needed, as an independent consultant with corporate development activities, and to assist with the strategic review process and Chris Seibert is no longer VP, Upstream Marketing of the Company. Mr. Seibert will continue to assist the Company, as needed, as an independent consultant with clinical and upstream marketing, and to assist with the strategic review process.